Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or Refractory, CD22- Positive, Follicular B-Cell Non Hodgkin’s Lymphoma https://kusajili.fr:443/Trial/dC50jzAlJUGNFUlLjxnb4w%24an-open-label-randomized-phase-3-study-of-inotuzumab-ozogamicin-cmc-544-administered-in-combination-with-rituximab-compared-to-
I have read and accept the terms of use of the site and the Privacy Policy
Send your message